Main Congress Day 1 - 22nd April @ 13:30
Start-Up Pitches
13:30 - Thomas Campi, CEO, Modulant Biosciences - 'Novel Antiviral to Treat PRRSv in Pigs'
13:35 - Robert Forgey, President & CEO, Iaso Therapeutics - 'Generate Novel Solutions that Simplify Vaccine Access'
13:40 - Gaurav Byagathvalli, Co-Founder & CEO, Piezo Therapeutics - ‘Delivering LNP-Free "Naked" mRNA Vaccines to Improve Reactogenicity, Valency, and Accessibility’
13:45 - Marty Anderson, COO, Profound Research - 'Integrating Clinical Research into Clinical Practice'
13:50 - Sander Wuyts, CEO, ImmuneWatch - 'Find the epitope specificity of your T-cell receptors with machine learning'
13:55 - Sarah Alsuleiman, Research & Development Scientist, Athari BioSciences, Inc. – ‘Revolutionizing Pathogenic Virus Surveillance and Treatment’
14:00 - Dr Yimy Mena, CEO and Director of Process Development, Pegasus Biotech Inc. - ‘Pegasus Biotech and the BPE technology’
14:05 - Michael Egan, CEO/CSO, CastleVax - 'CastleVax: Development of Next Generation Mucosal Vaccines for Respiratory Viruses and Pandemic Preparedness'
Thomas Campi, CEO,
Modulant Biosciences
Dr. Tom Campi is the CEO of Modulant Biosciences, an animal health biotechnology company focusing on therapies for infectious and chronic diseases. The current pipeline includes drugs for FIP, a fatal coronavirus in cats; Parvo, a serious enteric disease in dogs, PRRSv, a continuing problem for the ...
Robert Forgey, President & Chief Executive Officer,
Iaso Therapeutics, Inc.
Robert W. Forgey is a seasoned life sciences executive and entrepreneur with a proven track record of driving success in both emerging and established companies. As President & CEO of Iaso Therapeutics, he spearheads the company's strategic vision, securing crucial seed funding and guiding...
Gaurav Byagathvalli, Co-Founder and CEO,
Piezo Therapeutics, Inc.
Gaurav is scientist, innovator, and entrepreneur, serving as the CEO and Co-Founder of Piezo Therapeutics. Prior to Piezo, he served in a variety of roles at Moelis and Company, Capital One, and Elevance Health. He’s a published scientist with a background in drug delivery and synthetic...
Sander Wuyts, ImmuneWatch,
ImmuneWatch
Dr. Sander Wuyts is the founder and CEO of ImmuneWatch.
His mission is to help researchers find the specificity of their T-cell receptors. This is useful for clinical-stage biotech and pharma companies as well as academics who use T-cell receptor sequencing as a way to evaluate the efficacy of...
Michael Egan, CEO/CSO,
CastleVax
Dr. Egan brings to CastleVax 25+ years of vaccine research and development experience. Prior to joining CastleVax, Dr. Egan served as the Chief Scientific Officer of Auro Vaccines LLC. Previously, Dr. Egan served as a Project Leader at the Bill and Melinda Gates Medical Research Institute and led a ...
Tim Hirst, CEO,
GPN Vaccines Ltd
Dr Tim Hirst is the Chairman and CEO of GPN Vaccines (https://gpnvaccines.com) an Australian biotechnology company conducting clinical trials of a new vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae. He is an entrepreneur, investor and internationally acclaimed...
Yimy Mena, CEO and Director of Process Development,
Pegasus Biotech Inc.
Dr. Yimy Mena graduated with a chemical engineering degree from the National University of Colombia and completed both his MSc and Doctorate degrees in Biotechnology at the National Autonomous University of Mexico. With more than 20 years of industry experience in both small and large...
Sarah Alsuleiman, Research and Development Scientist,
Athari BioSciences
Sarah is a motivated research and development scientist with a background in molecular biology and infectious diseases. During her undergraduate years, Sarah was the recipient of nationally recognized research awards including the Barry Goldwater scholarship and the IDeA Networks of Biomedical...
Marty Anderson, Chief Operating Officer,
Profound Research
Marty Forrest Anderson serves as the Chief Operations Officer (COO) at Profound Research, a leading clinical trial site network. With over 30 years of experience in the clinical trial industry, Marty has been instrumental in spearheading operations since the company's inception.
Prior to...
Sally Mossman, VP, Head of Research Portfolio Strategy,
Sanofi Vaccines
Sally Mossman heads up the portfolio of research and early development stage programs at Sanofi Vaccines and sits on the Vaccines R&D Leadership Team for the company. Many of the novel programs in her portfolio are leveraging Sanofi’s proprietary mRNA technology accessed through the...
